Form 8-K PRA Health Sciences, For: Jul 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Binance sees spike in withdrawals as exchange returns online after $6.3 billion heist
- Oracle files to offer $10B in common stock alongside senior notes
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
PRA Health Sciences (PRAH) Tops Q2 EPS by 7c, Raises FY15 EPS Guidance
July 27, 2015 5:11 PM EDTPRA Health Sciences (NASDAQ: PRAH) reported Q2 EPS of $0.47, $0.07 better than the analyst estimate of $0.40. Revenue for the quarter came in at $336.5 million versus the consensus estimate of $336.74 million.
PRA Health Sciences sees FY2015 EPS of $1.75-$1.85, versus prior guidance of $1.62-$1.72 and... More



